Abstract:Background: The effectiveness of immunotherapy varies significantly among patients with advanced non-small cell lung cancer (NSCLC). This study investigates distinct subpopulations of CD4+T cells in the peripheral blood of stage IV NSCLC patients treated with anti-PD-1 combined with chemotherapy to identify immune mechanisms and systemic markers associated with treatment response or failure. Methods: We analyzed a cohort of 33 treatment-naive stage IV NSCLC patients, categorizing them as responders or non-responders based on clinical outcomes at 9 weeks and 6 months post-therapy initiation. Peripheral blood mononuclear cells (PBMCs) were collected before treatment, and high-dimensional flow cytometry was employed to profile immune cell subpopulations. Additionally, single-cell RNA sequencing (scRNAseq) data from both the same patients in our cohort and an independent cohort were analyzed to expand and validate the findings. Results: Non-responders exhibited elevated levels of suppressive phenotype CD4+ T lymphocytes expressing IL-10, CTLA-4, and other inhibitory markers like CD161 and CD95. Conversely, responders showed higher frequencies of activated CD4+CD69+ T lymphocytes, as well as increased percentages of TCF-1+ Effector Memory, Effector, and Central Memory CD4+ T cells. Responders also demonstrated higher levels of TCF7 and CXCR3 expression, markers associated with effective T cell activation and migration to the tumor microenvironment. Furthermore, single-cell RNA sequencing from the same cohort revealed differentially expressed genes in CD4+ T cells between responders and non-responders. Responders exhibited upregulation of cytotoxic genes such as NKG7 and GNLY and downregulation of genes like IL7R. Non-responders had higher levels of CTLA4 and KLRB1 expression, markers associated with immune suppression. ROC analysis showed that the frequencies of CD4+IL-10+ and CD4+TCF-1+ T cells could predict response with an AUC of 0.84 (p < 0.007). Finally, an in vitro dual blockade study with anti-PD-1/CTLA-4 using non-responder PBMC demonstrated that combining these two drugs significantly increased IFN-gamma and granzyme B production in CD4+ and CD8+ T cells. Conclusion: This study highlights the critical role of distinct CD4+ T cell subpopulations in predicting therapeutic outcomes in NSCLC patients undergoing anti-PD-1 therapy with chemotherapy. These findings provide valuable insights into the immune mechanisms driving response to immunotherapy and propose potential biomarkers for patient stratification. Citation Format: Amanda Figueiredo, Guilherme Evangelista, Clara Cavalcanti, Kátia Morais, Thaiany Goulart Souza-Silva, Robert Balderas, Rodrigo Pestana Lopes, Juan Santos e Silva, Jonathan Avila, Helder Nakaya, Nayane Galdino, Larissa Melo Kuil, Ananda Domingues Lopes, James Turner, Helano Freitas, Jefferson Luiz Gross, Walderez O Dutra, Valdemir Lima, Kenneth J Gollob. Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-01.

EP076/#303 Immune and Inflammation-Related Factors Alteration As a Biomarker for Predicting Prognosis and Responsiveness to PD-1 Monoclonal Antibody in Patients with Recurrent Cervical Cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Abstract 6428: Transcriptome analysis of tissues and peripheral blood revealed potential biomarkers for chemo/radio-immunotherapy in non-small cell lung cancer

Clinical Significance of Peripheral T-cell Receptor Repertoire Profiling and Individualized Nomograms in Patients with Gastrointestinal Cancer Treated with Anti-Programmed Death 1 Antibody.

Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma

Predictive Value of the Biomarker of Peripheral Blood of Lung Carcinoma Patients Responding to PD-1 Treatment: A Real-Word Study.

Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor

Development and Validation of an Individualized Immune-Related Gene Pairs Prognostic Signature in Papillary Renal Cell Carcinoma

Abstract PR-01: Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy

Immune signatures of patients with advanced non-small-cell lung cancer for efficacy prediction after immunotherapy

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy

Biomarkers of response to PD-1/PD-L1 inhibition

Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients